Drug - Stivarga (regorafenib) [Bayer HealthCare Pharmaceuticals Inc.]
February 2013
Therapeutic Area - Oral Oncology
OR
Stivarga is a kinase inhibitor indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. NCCN Colon Cancer Guidelines Version 3.2013 indicates that regorafenib is a treatment option after first, second, or third progression, depending on previous lines of therapy. Best supportive care and clinical trial is also listed as an alternate option to regorafenib.
MHCP Provider Call Center 651-431-2700 or 800-366-5411